Compounded Tirzepatide vs Zepbound and Mounjaro

Brand-name tirzepatide costs roughly $1,499 per month. Compounded tirzepatide starts at $129. The compounded vs brand tirzepatide decision is one every patient faces, and price is not the only variable. FDA oversight, manufacturing standards, insurance eligibility, formulation consistency and legal status all differ between the two options. This page lays out exactly what you gain and what you give up with each choice.

What Is the Difference?

The active molecule is the same: tirzepatide. How it gets manufactured, tested, regulated and delivered to you is not.

FDA-Approved Brand Names: Zepbound and Mounjaro

Two brand-name tirzepatide products exist. Zepbound is FDA-approved for chronic weight management in adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related comorbidity. Mounjaro is FDA-approved for type 2 diabetes, not weight loss, though physicians frequently prescribe it off-label for weight management. Both are manufactured by Eli Lilly under current good manufacturing practice (cGMP) standards and have undergone the full FDA review process for safety, efficacy and quality.

The SURMOUNT clinical trial program tested brand-name tirzepatide in thousands of participants. SURMOUNT-1 showed 15.0%, 19.5% and 20.9% weight loss at the 5 mg, 10 mg and 15 mg doses respectively over 72 weeks (PMID 35658024). SURMOUNT-5 demonstrated 20.2% weight loss with tirzepatide versus 13.7% with semaglutide in a head-to-head comparison (PMID 40353578). All of that data applies to the brand-name formulation.

Compounded Tirzepatide from 503A Pharmacies

Compounded tirzepatide is prepared by licensed compounding pharmacies based on individual prescriptions from licensed providers. Section 503A pharmacies operate under state board oversight and compound medications on a per-patient basis. They are not required to register with the FDA or follow cGMP standards, though many voluntarily adopt quality controls that exceed minimum requirements.

A compounded product is not a generic. Generic drugs go through an abbreviated FDA approval process that requires demonstration of bioequivalence to the brand-name product. Compounded tirzepatide does not undergo this process. The active ingredient is the same molecule, but no regulatory body has verified that the compounded product delivers the same dose in the same way over the same timeframe.

Price Comparison

The cost difference between compounded and brand-name tirzepatide is the single biggest factor driving patients toward compounding pharmacies. The gap is enormous.

A patient paying full list price for Zepbound spends $17,988 per year. The same patient using BiltRx compounded tirzepatide spends $1,548. That is a savings of $16,440 annually. Even Arc-1 at its highest listed dose saves over $13,000 per year compared to brand-name. These numbers explain the rapid growth of the compounded tirzepatide market. For a direct comparison between BiltRx and Arc-1, see our provider comparison page.

What You Get with Brand-Name Tirzepatide

Eli Lilly Manufacturing Standards

Zepbound and Mounjaro are manufactured by Eli Lilly in FDA-inspected facilities that follow cGMP. Every batch undergoes potency testing, sterility testing, stability testing and quality assurance review before release. The autoinjector pen is designed to deliver a precise dose. The drug's pharmacokinetic profile has been characterized through extensive studies. When a physician prescribes Zepbound 10 mg, the patient receives exactly 10 mg of tirzepatide in a validated delivery system.

This level of manufacturing consistency is what the SURMOUNT trials were built on. The efficacy numbers, the safety data and the side effect frequencies all reflect a product manufactured to these standards. Patients using brand-name tirzepatide can be confident they are getting the same product that produced a 20.9% average weight loss at the highest dose in SURMOUNT-1.

Insurance and Copay Programs

Brand-name tirzepatide is eligible for insurance coverage. Coverage varies widely by insurer, plan and indication. Mounjaro coverage for type 2 diabetes is more common than Zepbound coverage for weight management because many insurers still classify obesity medications as non-essential. Eli Lilly has offered manufacturer savings programs and copay cards that reduce patient costs, sometimes to as low as $25 per month for eligible commercially insured patients.

Patients with type 2 diabetes may find that Mounjaro is covered under their pharmacy benefit with a manageable copay. Patients seeking Zepbound for weight loss face a harder path. If your insurer covers Zepbound, the out-of-pocket cost may be comparable to or lower than compounded alternatives. If it does not, you face the full list price. Checking your specific plan's formulary is an essential first step. Our effectiveness page provides context on the clinical data supporting coverage requests.

What You Get with Compounded Tirzepatide

Lower Cost

This is the primary draw. At $129 per month from BiltRx, compounded tirzepatide costs less than 9% of the brand-name list price. For patients without insurance coverage for Zepbound or Mounjaro, the math is simple. A medication that costs $18,000 per year is inaccessible to most Americans paying out of pocket. A medication that costs $1,548 per year is within reach for a much larger population.

The lower cost makes tirzepatide treatment sustainable over the long term. Weight management with GLP-1 agonists is not a short course. The SURMOUNT-4 trial showed that stopping tirzepatide leads to significant weight regain. Ongoing treatment means ongoing cost. A price that patients can maintain for years matters more than one they can afford for a few months.

Telehealth Convenience

Both BiltRx and Arc-1 conduct medical consultations online. There is no office visit, no waiting room and no separate pharmacy trip. The patient fills out a health questionnaire, a licensed provider evaluates it remotely and the medication ships to the patient's address. For patients in areas with limited access to obesity medicine specialists or for those with scheduling constraints, telehealth ordering removes barriers that might otherwise delay treatment.

What You Give Up

Compounded tirzepatide has not undergone FDA review. This is not a technicality. It means no regulatory body has verified that a specific compounded product is bioequivalent to Zepbound. Potency can vary between compounding pharmacies and potentially between batches from the same pharmacy. Sterility testing protocols are determined by the compounding pharmacy, not mandated by the FDA. Stability data, which determines shelf life and storage requirements, may not match the brand-name product's validated profile.

There are also no clinical trial results for compounded tirzepatide. The 20.9% weight loss figure from SURMOUNT-1 was achieved with brand-name tirzepatide manufactured by Eli Lilly. Whether a compounded version produces identical results in a given patient is unknown and untested in controlled settings. The active molecule is the same, but differences in formulation, concentration accuracy and delivery method could affect absorption and therapeutic response.

Regulatory Context

Compounding has a legal framework in the United States, but it exists in a regulatory space that is distinct from the standard drug approval pathway. Understanding where compounded tirzepatide fits in that framework helps clarify what protections patients have and what gaps remain.

FDA Stance on Compounding

The FDA does not approve compounded medications. It has stated repeatedly that compounded drugs are not evaluated for safety, effectiveness or quality before patients use them. In 2023 and 2024, the FDA issued multiple warnings about compounded GLP-1 receptor agonists, citing concerns about products that may contain salt forms of semaglutide or tirzepatide that differ from the FDA-approved active ingredient.

Section 503A of the Federal Food, Drug, and Cosmetic Act allows compounding pharmacies to prepare medications based on individual prescriptions as long as they meet certain conditions. These include operating under a valid prescription, not making copies of commercially available products and complying with state pharmacy board regulations. The exception for compounding copies of commercially available drugs narrows when the brand-name product is on the FDA's drug shortage list.

Drug Shortage Exception

Tirzepatide has appeared on the FDA's drug shortage list at various points since its approval. While a drug is listed as in shortage, compounding pharmacies can legally prepare copies of that drug even though the brand-name product exists. This exception is the legal basis for much of the compounded tirzepatide market.

If tirzepatide is removed from the shortage list, the legal landscape shifts. Compounding pharmacies would need to stop producing copies of commercially available tirzepatide unless they qualify under other exemptions. The FDA has signaled its intent to enforce this distinction. Patients and providers should monitor the shortage status and be prepared for potential supply disruptions if the legal basis for compounding changes.

The regulatory situation is fluid. What is legally available today may not be available next year. Patients building a long-term weight management plan around compounded tirzepatide should factor in this uncertainty. Brand-name products do not carry this supply risk, though they carry the cost burden that drives patients to compounding in the first place. For more on how physicians view this trade-off, see our doctor review page.